Plazomicin

Plazomicin, sold under the brand name Zemdri, is a next-generation aminoglycoside ('neoglycoside') antibacterial derived from sisomicin by appending a hydroxy-aminobutyric acid (HABA) substituent at position 1 and a hydroxyethyl substituent at position 6'. Plazomicin, sold under the brand name Zemdri, is a next-generation aminoglycoside ('neoglycoside') antibacterial derived from sisomicin by appending a hydroxy-aminobutyric acid (HABA) substituent at position 1 and a hydroxyethyl substituent at position 6'. Plazomicin has been reported to demonstrate in vitro synergistic activity when combined with daptomycin or ceftobiprole versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant S. aureus (VRSA) and against Pseudomonas aeruginosa when combined with cefepime, doripenem, imipenem or piperacillin/tazobactam. It also demonstrates potent in vitro activity versus carbapenem-resistant Acinetobacter baumannii. In 2012, U.S. Food and Drug Administration granted fast track designation for the development and regulatory review of plazomicin. It was developed by Achaogen, Inc. to treat serious bacterial infections due to multidrug-resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE) and was approved by the US FDA on June 25, 2018. Plazomicin is approved by the FDA for adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Enterobacter cloacae, in patients who have limited or no alternative treatment options. Zemdri is an intravenous infusion, administered once daily. The FDA declined approval for treating bloodstream infections due to lack of demonstrated effectiveness. Plazomicin in the international nonproprietary name (INN).